BENDAMUSTINE

作品数：12被引量：12H指数：2
导出分析报告
相关领域：医药卫生更多>>
相关作者：程卯生任健孔芳更多>>
相关机构：沈阳药科大学山东大学更多>>
相关期刊：《Frontiers of Medicine》《Journal of Cancer Therapy》《药学进展》《Chinese Medical Journal》更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience
《Oncology Research》2024年第6期1031-1036,共6页CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH LUBOMIR SOKOL HAYDER SAEED JAVIER PINILLA SAMEH GABALLA 
Extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone lymphoma.Frontline bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s lymphomas.Only one tria...
关键词：Extranodal marginal zone lymphoma BENDAMUSTINE RITUXIMAB Front-line therapy 
Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease:a multicenter study
《China Medical Abstracts(Internal Medicine)》2023年第4期235-236,共2页吴弘英 
Objective To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone(BPD regimen)in the treatment of relapsed multiple myeloma(MM)with extramedullary disease.Methods This open,sin...
关键词：MEDULLARY RELAPSE MYELOMA 
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
《World Journal of Virology》2021年第6期312-325,共14页Valentina Bonuomo Isacco Ferrarini Michele Dell'Eva Eugenio Sbisà Mauro Krampera Carlo Visco 
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection now has a global resonance and represents a major threat for several patient populations.Observations from initial case series suggested that cancer...
关键词：LYMPHOMA SARS-CoV-2 infection Hematological malignancies COVID-19 RITUXIMAB BENDAMUSTINE 
Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study被引量：3
《Chinese Medical Journal》2021年第11期1299-1309,共11页Yuan-Kai Shi Xiao-Nan Hong Jian-Liang Yang Wei Xu Hui-Qiang Huang Xiu-Bin Xiao Jun Zhu Dao-Bin Zhou Xiao-Hong Han Jian-Qiu Wu Ming-Zhi Zhang Jie Jin Xiao-Yan Ke Wei Li De-Pei Wu Shen-Miao Yang Xin Du Yong-Qian Jia Ai-Chun Liu Dai-Hong Liu Zhi-Xiang Shen Lian-Sheng Zhang Leonard James Edward Hellriegel 
by the Teva Branded Pharmaceutical Products R&D Inc.
Background:Bendamustine was approved in China on May 26th,2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma(NHL).The current study was the registration trial...
关键词：BENDAMUSTINE Non-Hodgkin lymphoma B-cell malignancy Relapsed disease Clinical trial 
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
《Cancer Drug Resistance》2021年第1期208-222,共15页Issa Ismail Issa Rasmus Froberg Brøndum Hanne Due Linnea Schmidt Martin Bøgsted Karen Dybkær 
Aim:Bendamustine is primarily used for treatment of indolent lymphomas but has shown efficacy in some patients with diffuse large B-cell lymphoma(DLBCL)and multiple myeloma(MM).Molecular-based patient stratification f...
关键词：BENDAMUSTINE diffuse large B-cell lymphoma multiple myeloma resistance gene signature 
Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice
《The Journal of Biomedical Research》2018年第6期442-453,共12页Minbo Zang Qiao Zhou Yunfei Zhu Mingxi Liu Zuomin Zhou 
Non-Hodgkin lymphoma(NHL) is one of the most common cancers affecting men of reproductive age. The high response rate of bendamustine as first-line treatment for NHL, coupled with young age of patients, makes elucidat...
关键词：Non-Hodgkin lymphoma CHEMOTHERAPY BENDAMUSTINE MICE SPERMATOZOA TOXICOLOGY 
Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia
《Journal of Cancer Therapy》2018年第7期576-587,共12页Carolina Reyes Genevieve Gauthier Sherry Shi Annie Guerin 
Background: Bendamustine-based regimens are often used in the management of patients with chronic lymphocytic leukemia (CLL) but few studies have analyzed the comorbidity- and/or adverse event (CAE)-related healthcare...
关键词：Chronic LYMPHOCYTIC Leukemia Relapse/Refractory BENDAMUSTINE Economic BURDEN Overall Survival ADVERSE Events 
Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock
《Frontiers of Medicine》2014年第2期254-258,共5页Muhammad Furqan Yamei Chen Akintunde Akinleye Judy Sarungbam Alan Gass Karen Seiter Delong Liu 
Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage ...
关键词：mantle cell lymphoma BENDAMUSTINE cardiogenic shock 
Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins被引量：1
《Acta Biochimica et Biophysica Sinica》2013年第8期683-691,共9页Bo Lu Juan Li Jingxuan Pan Beihui Huang Junru Liu Dong Zheng 
Bendamustine is a bifunctional alkylating agent with some efficacy in the treatment of newly diagnosed and relapsed/re- fractory multiple myeloma （MM）. Everolimus, an mamma- lian target of rapamycin （mTOR） inhibit...
关键词：EVEROLIMUS BENDAMUSTINE MYELOMA SYNERGY apoptosis 
Bendamustine或将成为霍奇金淋巴瘤的一线标准治疗药
《药学进展》2010年第3期133-133,共1页范鸣 
关键词：BENDAMUSTINE 霍奇金淋巴瘤 一线标准治疗药 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部